Motor Symptom Treatment in Parkinson’s Disease

The pharmacologic management of motor symptoms in Parkinson’s disease (PD) is built on a foundation of dopaminergic replacement — most powerfully through levodopa — supplemented by monoamine oxidase type B (MAO-B) inhibitors, dopamine agonists (DAs), catechol-O-methyltransferase (COMT) inhibitors, and other adjunctive agents. Over four decades of randomized controlled trials, the treatment landscape has evolved considerably: the once-pervasive fear of early levodopa has been overturned, the role of MAO-B inhibitors as first-line adjuncts has been clarified, and the limitations of dopamine agonists — including impulse control disorders — are better understood. This article reviews the evidence base for each drug class, anchored in landmark trials and the MDS Evidence-Based Medicine Reviews.

🔹 Bottom Line: PD Motor Treatment

  • Levodopa remains the most effective motor therapy at all stages of PD. The LEAP trial definitively showed that early levodopa initiation does not accelerate disease progression — ending decades of levodopa-phobia.
  • MAO-B inhibitors (selegiline, rasagiline, safinamide) are clinically useful as monotherapy in mild early PD and as adjuncts in treated PD. PD MED showed MAO-B inhibitors were superior to COMT inhibitors as first adjunct therapy.
  • Dopamine agonists (pramipexole, ropinirole, rotigotine) reduce early motor complications compared to levodopa (CALM-PD: 28% vs 51%), but provide less motor improvement and carry risks of impulse control disorders, somnolence, and hallucinations. Long-term disability is equivalent.
  • COMT inhibitors (entacapone, opicapone, tolcapone) extend levodopa effect and reduce OFF time, but ranked below MAO-B inhibitors in head-to-head comparison (PD MED).
  • Choice of initial therapy depends on age, symptom severity, functional impairment, cognitive status, and patient priorities. The MDS EBM Review (Fox et al., 2018) rates levodopa, non-ergot DAs, selegiline, and rasagiline as “clinically useful” for monotherapy in early PD.

Levodopa

Levodopa, the metabolic precursor to dopamine, remains the gold standard for treating PD motor symptoms more than 50 years after its introduction. Administered with a peripheral aromatic amino acid decarboxylase (AADC) inhibitor — carbidopa or benserazide — to prevent peripheral conversion and reduce nausea, levodopa provides the most robust improvement in bradykinesia, rigidity, and tremor of any available agent. The MDS EBM Review (Fox et al., 2018) designates oral levodopa as “clinically useful” for both early PD monotherapy and adjunctive therapy(1).

ELLDOPA: The Dose-Response — and the Paradox

The ELLDOPA trial (Fahn et al., 2004) was the first large RCT to rigorously evaluate the dose-dependent effects of levodopa in early PD. A total of 361 patients with early, untreated PD were randomized to carbidopa-levodopa at 150, 300, or 600 mg/day, or placebo for 40 weeks, followed by a 2-week washout period to distinguish symptomatic from disease-modifying effects(2).

Results were striking: levodopa improved UPDRS scores in a clear dose-dependent fashion. After the 2-week washout, the 600 mg/day group still showed net improvement compared to baseline (UPDRS change −1.4 points vs +7.8 for placebo, P<0.001). Even the lower doses showed less worsening than placebo (150 mg: +1.9; 300 mg: +0.4). However, an imaging substudy using [123I]β-CIT SPECT showed greater dopamine transporter decline in levodopa-treated patients (−7.2% vs −1.4%, P=0.036) — raising the possibility that levodopa might accelerate nigrostriatal degeneration. Dyskinesias occurred in 16.5% of the 600 mg group versus 3.3% of placebo(2).

The DaT-SPECT finding generated considerable debate but was ultimately attributed to pharmacologic regulation of the transporter rather than true neurotoxicity — a conclusion supported by subsequent trials.

LEAP: Ending the Levodopa Controversy

The LEAP trial (Verschuur et al., 2019) used a delayed-start design — the most rigorous method to distinguish disease-modifying from symptomatic effects — to definitively address whether early levodopa alters PD progression. A total of 445 patients with early PD were randomized to either levodopa 300 mg/day for 80 weeks (early-start) or placebo for 40 weeks followed by levodopa for 40 weeks (delayed-start)(3).

The primary endpoint — change in total UPDRS from baseline to week 80 — showed no significant difference between groups (−1.0 vs −2.0 points; difference 1.0; 95% CI −1.5 to 3.5; P=0.44). Rate of symptom progression during the treatment phase was similar (0.04 vs 0.06 UPDRS points/week). Quality of life, cognition, and depression scores were also equivalent. Motor complications were uncommon and similar between groups(3).

🔹 Clinical Relevance: Starting Levodopa — The Fear Is Over

  • LEAP showed that early levodopa neither accelerates nor slows disease progression — it is a purely symptomatic therapy with no evidence of neurotoxicity.
  • Delaying levodopa to “save it for later” provides no long-term advantage and withholds the most effective symptomatic therapy from patients who need it.
  • Motor complications (wearing off, dyskinesias) are primarily driven by disease duration and disease severity, not by cumulative levodopa exposure.
  • The clinical decision is straightforward: when PD motor symptoms cause functional impairment, start levodopa.

PD MED: The Pragmatic Comparison

The PD MED trial (PD MED Collaborative Group, 2022) was a large, open-label, pragmatic RCT that compared levodopa, dopamine agonists, and MAO-B inhibitors as initial monotherapy in early PD, and compared dopamine agonists, MAO-B inhibitors, and COMT inhibitors as first adjunct therapy in patients already on levodopa(4).

In the initial therapy arm, all three classes provided effective motor control with no significant difference in the primary outcome (PDQ-39 mobility) over long-term follow-up (median 4.4 years). In the adjunct therapy arm (500 patients with motor complications), MAO-B inhibitors were significantly superior to COMT inhibitors in PDQ-39 mobility (+4.2 points, P=0.03) and EQ-5D utility (+0.05, P=0.04). There was no significant difference between dopamine agonists and MAO-B inhibitors. Trends favored MAO-B inhibitors for lower rates of dementia and mortality versus COMT inhibitors, though these were not statistically significant(4).

Levodopa Formulations

Several levodopa formulations are available. Immediate-release (IR) carbidopa-levodopa (Sinemet, generics) is the standard; doses are titrated from 25/100 mg three times daily. Controlled-release (CR) carbidopa-levodopa (Sinemet CR) was designed to reduce wearing off but has erratic absorption and lower bioavailability (~70% of IR), limiting its predictability. Extended-release (ER) carbidopa-levodopa (IPX066/Rytary) provides a more sustained levodopa profile through a combination of immediate and delayed-release beads, reducing OFF time versus IR in the ADVANCE-PD trial. Carbidopa-levodopa enteral suspension (CLES/Duopa) and subcutaneous levodopa infusions are covered separately under Infusion and Device Therapies.

MAO-B Inhibitors

Monoamine oxidase type B (MAO-B) inhibitors block the enzymatic degradation of dopamine in the striatum, providing a modest but clinically meaningful symptomatic benefit. Three agents are available: selegiline, rasagiline, and safinamide. The MDS EBM Review rates selegiline and rasagiline as “clinically useful” for early PD monotherapy and as adjunct therapy; safinamide is designated clinically useful as adjunct to levodopa(1).

DATATOP: Selegiline in Early PD

The DATATOP trial (Parkinson Study Group, 1989) was one of the earliest major RCTs in PD, randomizing 800 patients with untreated early PD to selegiline (deprenyl) 10 mg/day, tocopherol (vitamin E) 2000 IU/day, both, or placebo. The primary endpoint was time to disability requiring levodopa initiation(5).

Selegiline significantly delayed the need for levodopa by approximately 9 months (P<0.001). Tocopherol showed no benefit. UPDRS and Schwab-England ADL scores improved or stabilized in selegiline-treated patients. The key debate was whether selegiline’s benefit was symptomatic (masking progression) or disease-modifying (actually slowing neurodegeneration). Subsequent analyses, including washout studies, supported a primarily symptomatic mechanism with possible modest neuroprotective effects(5).

ADAGIO: Rasagiline and the Disease-Modification Question

The ADAGIO trial (Olanow et al., 2009) used a delayed-start design — similar in concept to LEAP but applied to rasagiline — in 1,176 patients with untreated early PD. Patients were randomized to early-start rasagiline (1 mg or 2 mg/day for 72 weeks) or delayed-start (placebo for 36 weeks, then rasagiline for 36 weeks). Three hierarchical endpoints were required for a disease-modification conclusion: (1) superiority of rasagiline over placebo in rate of UPDRS worsening during weeks 12–36, (2) superiority of early-start over delayed-start in UPDRS at 72 weeks, and (3) non-inferiority in the rate of UPDRS change during weeks 48–72(6).

Rasagiline 1 mg/day met all three endpoints: UPDRS worsening rate was slower in the early-start group (0.09 vs 0.14 points/week, P=0.01), week 72 UPDRS scores were better in the early-start group (2.82 vs 4.50, P=0.02), and slopes converged in the final period. However, 2 mg/day failed: no significant difference at 72 weeks (3.47 vs 3.11, P=0.60). This dose-discordance — where the lower dose met disease-modification criteria but the higher dose did not — undermined a straightforward neuroprotective interpretation, and the results are now generally considered to reflect symptomatic benefit(6).

Safinamide

Safinamide has a dual mechanism: selective, reversible MAO-B inhibition combined with state-dependent sodium channel blockade and glutamate release modulation. As adjunct to levodopa in fluctuating PD, safinamide 100 mg/day increased daily ON time by approximately 1.4 hours and reduced OFF time compared to placebo in the SETTLE and Study 016 trials. It is not approved as monotherapy. Safinamide’s glutamatergic properties make it theoretically attractive for both motor symptoms and motor complications, though its role relative to rasagiline as an adjunct remains debated(1).

Dopamine Agonists

Dopamine agonists directly stimulate dopamine receptors, bypassing the need for presynaptic conversion. Non-ergot agents — pramipexole, ropinirole, and rotigotine — are the current standard; ergot-derived agonists (cabergoline, pergolide, bromocriptine) are no longer recommended due to the risk of cardiac valvulopathy and retroperitoneal/pleuropulmonary fibrosis. The MDS EBM Review designates all non-ergot DAs as “clinically useful” for monotherapy and adjunctive therapy(1).

CALM-PD: The DA-vs-Levodopa Debate

The CALM-PD trial (Parkinson Study Group, 2000) was the landmark comparison of initial dopamine agonist versus levodopa therapy. A total of 301 patients with early PD were randomized to pramipexole (titrated to 1.5 mg TID) or levodopa (titrated to 25/100 mg TID), with open-label levodopa supplementation permitted from week 11 in both groups(7).

Over 23.5 months, pramipexole reduced the risk of dopaminergic motor complications by 55%: 28% of pramipexole patients developed any complication (wearing off, dyskinesia, or on-off fluctuations) versus 51% with levodopa (HR 0.45, P<0.001; NNT ≈ 4). Dyskinesias were dramatically lower (9.9% vs 30.7%, HR 0.33, P<0.001) and wearing off was also reduced (23.8% vs 38.0%, HR 0.57, P=0.01). However, levodopa provided substantially greater motor improvement: UPDRS total score improved by 9.2 points with levodopa versus 4.5 points with pramipexole (P<0.001). Quality of life scores also favored levodopa (PDQUALIF, P=0.006). Pramipexole was associated with significantly more somnolence (32.4% vs 17.3%, P=0.003), hallucinations, and peripheral edema(7).

CALM-PD Long-Term Follow-Up (6 Years)

The 6-year open-label extension of CALM-PD (Parkinson Study Group, 2009) enrolled 222 of the original 301 participants. By this time, >90% of patients in both groups were receiving levodopa, regardless of initial assignment. The critical finding: self-reported disability was equivalent between the initial-pramipexole and initial-levodopa groups (Schwab-England ADL: 79.9 vs 82.5, P=0.19). Motor complications remained significantly lower in the pramipexole-first group (50.0% vs 68.4%, P=0.002), but this did not translate into a functional advantage. Somnolence and edema remained more common with pramipexole(8).

The CALM-PD long-term data established a critical principle: initial therapy choice affects complication patterns but not long-term disability. The reduced motor complication rate with initial DA therapy comes at the cost of less effective early motor control and greater neuropsychiatric risk.

SP512: Rotigotine Transdermal Patch

The SP512 trial (Watts et al., 2007) evaluated the rotigotine transdermal patch (2–6 mg/24h) versus placebo in 277 patients with early PD over 24 weeks. The responder rate (≥20% reduction in UPDRS II+III) was significantly higher with rotigotine: 48% versus 19% (P<0.001). Mean UPDRS II+III scores improved by 15.1% with rotigotine versus worsening of 7.3% with placebo. Clinical Global Impression improvement was 57% versus 30% (P<0.001). The most common adverse events were application site reactions (44%), nausea (41%), and somnolence (33%)(9).

Rotigotine’s transdermal delivery provides stable 24-hour dopaminergic stimulation, which is useful for patients with swallowing difficulty, morning akinesia, or preference for non-oral administration. It is approved for both early PD monotherapy and advanced PD adjunctive therapy.

🔴 Impulse Control Disorders with Dopamine Agonists

  • Impulse control disorders (ICDs) — pathological gambling, hypersexuality, compulsive shopping, binge eating — occur in approximately 15–25% of patients on dopamine agonists and are the most clinically important safety concern with this drug class.
  • Risk factors include younger age, male sex, history of novelty-seeking personality traits, personal or family history of addiction, and higher DA dose.
  • The DOMINION study found ICDs in 13.6% of PD patients overall: prevalence was significantly higher in those on DAs (17.1%) versus not on DAs (6.9%).
  • All non-ergot DAs carry ICD risk — there is no “safer” agent within the class. Dose reduction or discontinuation is the primary management strategy.
  • DA Withdrawal Syndrome (DAWS) can occur when reducing or stopping DAs — manifesting as severe anxiety, dysphoria, panic, fatigue, pain, and autonomic dysfunction — complicating ICD management in 15–20% of patients.
  • Clinicians should screen for ICDs at every visit using direct questioning or validated instruments (e.g., QUIP-RS) and counsel patients and caregivers proactively at the time of DA initiation.

COMT Inhibitors

COMT inhibitors block the peripheral degradation of levodopa, extending its plasma half-life and increasing central dopamine availability. They have no independent antiparkinsonian activity and are used exclusively as levodopa adjuncts to reduce motor fluctuations (wearing off). Three agents are available:

Entacapone: The most widely used COMT inhibitor, dosed with each levodopa administration (200 mg per dose). The SEESAW, NOMECOMT, and Rinne studies demonstrated reduced OFF time by approximately 1–1.5 hours/day. It is also available as a fixed-dose combination with carbidopa-levodopa (Stalevo). The STRIDE-PD trial showed that initial therapy with levodopa-entacapone did not reduce motor complications compared to levodopa alone — in fact, it was associated with earlier onset of dyskinesia(1).

Opicapone: A once-daily, third-generation COMT inhibitor with no hepatotoxicity concerns. The BIPARK-I and BIPARK-II trials demonstrated reduced OFF time comparable to entacapone with the convenience of once-daily dosing. Opicapone 50 mg/day is now FDA- and EMA-approved.

Tolcapone: The most potent COMT inhibitor, but requires liver function monitoring every 2–4 weeks for the first 6 months due to rare hepatotoxicity (3 fatal cases reported). Reserved for patients who fail entacapone or opicapone.

As noted above, PD MED compared COMT inhibitors (predominantly entacapone) to MAO-B inhibitors as first adjunct therapy and found MAO-B inhibitors significantly superior in patient-rated mobility and quality of life, suggesting that MAO-B inhibitors should generally be the preferred first adjunct(4).

Other Agents

Amantadine

Amantadine is an NMDA receptor antagonist with additional dopaminergic and anticholinergic properties. Its primary role in PD is for the management of levodopa-induced dyskinesia (covered in detail in the Motor Complications article). For motor symptoms, amantadine provides modest improvement in bradykinesia and rigidity as monotherapy or adjunct, though it is not designated “clinically useful” as first-line therapy in the MDS EBM Review. An extended-release formulation (ADS-5102/Gocovri) is FDA-approved specifically for dyskinesia and OFF time in patients on levodopa(1).

Istradefylline

Istradefylline is a selective adenosine A2A receptor antagonist that reduces inhibitory output from the indirect pathway of the basal ganglia. It reduces OFF time by approximately 0.5–0.7 hours/day as adjunct to levodopa. FDA-approved in 2019, istradefylline (Nourianz) is designated as adjunctive treatment for patients experiencing OFF episodes. The MDS EBM Review identifies it as “clinically useful” as levodopa adjunct. Its non-dopaminergic mechanism makes it a useful option when adding further dopaminergic therapy is limited by side effects(1).

Anticholinergics

Trihexyphenidyl and benztropine are the classic anticholinergic agents, used primarily for tremor — particularly in younger patients with tremor-predominant PD. They provide modest tremor reduction but have significant cognitive side effects (confusion, memory impairment, hallucinations), urinary retention, constipation, and dry mouth. They should be avoided in patients over age 65 and in those with cognitive impairment. The MDS EBM Review designates trihexyphenidyl as “likely clinically useful” for motor symptoms but notes “unacceptable risk without specialized monitoring” for safety in older adults(1).

Clinical Decision Framework

The choice of initial therapy and the sequence of adjunct additions require balancing efficacy, side-effect profile, complication risk, and patient-specific factors. No single algorithm fits all patients, but the evidence supports several guiding principles:

Clinical Scenario Preferred Initial Therapy Rationale First Adjunct When Needed
Mild symptoms, minimal functional impact MAO-B inhibitor (rasagiline or selegiline) Modest efficacy sufficient; well-tolerated; once-daily dosing; may delay levodopa start by months (DATATOP, ADAGIO) Levodopa when functional impairment emerges
Moderate symptoms with functional impairment Levodopa (carbidopa-levodopa) Most effective motor therapy; early start does not alter progression (LEAP); dose-dependent benefit (ELLDOPA) MAO-B inhibitor preferred over COMT inhibitor (PD MED)
Young-onset PD (<50 years) Dopamine agonist ± MAO-B inhibitor Higher risk of motor complications; DA reduces dyskinesia risk (CALM-PD: 9.9% vs 30.7%); longer disease course Levodopa at lowest effective dose when DA insufficient
Older patient (>70) or cognitive impairment Levodopa Avoid DAs (hallucinations, somnolence, ICDs, cognitive risk); anticholinergics contraindicated; levodopa best tolerated MAO-B inhibitor or COMT inhibitor
Tremor-predominant PD Levodopa or DA; anticholinergic only in young patients Tremor responds variably; may need higher levodopa dose; anticholinergics most tremor-specific but cognitive risk limits use Agent from complementary class
Wearing off on levodopa — First optimize levodopa dosing (increase frequency, reduce interval) MAO-B inhibitor > COMT inhibitor (PD MED); DA or istradefylline if needed

🔹 Clinical Relevance: Practical Approach to Initial Therapy

  • Start levodopa when motor symptoms cause functional impairment. There is no benefit to delaying it (LEAP).
  • For very mild, nondisabling symptoms, a MAO-B inhibitor buys time and simplifies the regimen.
  • In younger patients with concerns about early dyskinesia, starting with a DA is reasonable — but levodopa will eventually be needed, and long-term disability is no different (CALM-PD Long-term).
  • When wearing off emerges, optimize levodopa dosing first (more frequent, smaller doses), then add a MAO-B inhibitor as the preferred first adjunct (PD MED).
  • Avoid anticholinergics in patients >65 or with any cognitive concern.
  • Screen for impulse control disorders at every visit when a DA is prescribed.

MDS EBM Efficacy Summary

The following table summarizes the MDS Evidence-Based Medicine Review (Fox et al., 2018) efficacy designations for each pharmacologic class across the major clinical indications(1):

Intervention Monotherapy (Early PD) Adjunct to Levodopa Practice Implication
Levodopa (IR) Efficacious — Clinically useful
Pramipexole (IR/ER) Efficacious Efficacious Clinically useful
Ropinirole (IR/PR) Efficacious Efficacious Clinically useful
Rotigotine (patch) Efficacious Efficacious Clinically useful
Selegiline Efficacious Efficacious Clinically useful
Rasagiline Efficacious Efficacious Clinically useful
Safinamide Insufficient evidence Efficacious Clinically useful (adjunct)
Entacapone — Efficacious Clinically useful
Opicapone — Efficacious Clinically useful
Tolcapone — Efficacious Clinically useful (requires LFT monitoring)
Amantadine (IR) Likely efficacious Insufficient evidence (for motor symptoms) Possibly useful
Istradefylline — Efficacious Clinically useful
Trihexyphenidyl Likely efficacious — Possibly useful (cognitive risk)

Trial Comparison Table

Trial Year N Population Intervention Comparator Primary Outcome Key Safety
DATATOP 1989 800 Early, untreated PD Selegiline 10 mg/d ± tocopherol Placebo ± tocopherol Time to levodopa: 667 vs 491 days (P<0.001) No increase in serious AEs
CALM-PD 2000 301 Early PD Pramipexole (up to 4.5 mg/d) Levodopa (up to 600 mg/d) Motor complications: 28% vs 51% (HR 0.45, P<0.001). UPDRS: 4.5 vs 9.2 (P<0.001 favoring levodopa) Somnolence 32% vs 17%; hallucinations; edema
ELLDOPA 2004 361 Early PD, untreated C/L 150, 300, or 600 mg/d Placebo UPDRS change (42 wk): −1.4 vs +7.8 (600 mg; P<0.001) DaT decline −7.2% vs −1.4%; dyskinesia 16.5% (600 mg)
SP512 Rotigotine 2007 277 Early PD Rotigotine patch 2–6 mg/24h Placebo patch Responder rate: 48% vs 19% (P<0.001) Skin reactions 44%; nausea 41%; somnolence 33%
ADAGIO 2009 1,176 Early, untreated PD Rasagiline 1 or 2 mg/d (early-start) Delayed-start (36 wk placebo → rasagiline) 1 mg met all 3 endpoints (P=0.02); 2 mg failed (P=0.60) Well tolerated; similar AE rates
CALM-PD Long-term 2009 222 Early PD (6-yr follow-up) Initial pramipexole → open-label Initial levodopa → open-label S/E ADL: 79.9 vs 82.5 (P=0.19 — no difference) Motor complications lower with initial pramipexole (50% vs 68%, P=0.002)
LEAP 2019 445 Early PD, untreated Levodopa 300 mg/d × 80 wk (early-start) Placebo 40 wk → levodopa 40 wk UPDRS at 80 wk: −1.0 vs −2.0 (P=0.44 — no difference) Similar AEs and motor complications
PD MED 2022 1,620 PD with motor complications (adjunct arm: n=500) DA, MAO-Bi, or COMT-i added to levodopa Each other (3-way comparison) MAO-Bi > COMT-i: PDQ-39 mobility +4.2 (P=0.03); DA vs MAO-Bi: NS Trends toward less dementia with MAO-Bi vs COMT-i

Pharmacotherapeutic Reference Table

Drug Class Generic Name Trade Name(s) Mechanism Metabolism / Half-Life Typical Dosing Approved Use Key Side Effects Clinical Pearls
Levodopa Carbidopa-levodopa (IR) Sinemet, Parcopa (ODT), generics Dopamine precursor; converted to dopamine by AADC in CNS. Carbidopa/benserazide block peripheral AADC Plasma t½ 1–1.5h (IR); hepatic & peripheral decarboxylation 25/100 mg TID; titrate to 25/250 mg TID–QID Monotherapy & combination; all stages Nausea, dyskinesia, orthostatic hypotension, somnolence, hallucinations (advanced disease) Most effective motor therapy. Take 30–60 min before meals for best absorption (competes with dietary amino acids)
Carbidopa-levodopa (CR) Sinemet CR Plasma t½ extended but erratic absorption; ~70% bioavailability of IR 25/100 or 50/200 mg BID–QID Wearing off; nocturnal akinesia Same as IR Unreliable absorption limits utility; often requires ~30% higher daily dose than IR
Carbidopa-levodopa (ER) Rytary (IPX066) Immediate + delayed-release beads; more sustained levels than IR 23.75/95 to 97.5/390 mg TID–5×/day Motor fluctuations; wearing off Same as IR Reduces OFF time vs IR (ADVANCE-PD); complex dose conversion from IR (~30% increase in total daily levodopa)
Levodopa-benserazide Madopar, Prolopa Plasma t½ 1–1.5h; similar to carbidopa-levodopa 100/25 mg TID–QID Monotherapy & combination (available outside US) Same as IR Standard levodopa formulation in Europe, Canada, Asia. Also available as dispersible (Madopar Dispersible) for rapid onset
MAO-B Inhibitors Selegiline Eldepryl, Zelapar (ODT), Emsam (patch — for depression only) Irreversible, selective MAO-B inhibitor → reduces striatal dopamine breakdown Hepatic (CYP2B6, 2C19, 3A4) → amphetamine metabolites (l-methamphetamine, l-amphetamine); t½ 10h 5 mg BID (conventional); Zelapar 1.25–2.5 mg/day (ODT, bypasses first-pass) Monotherapy (early PD); adjunct to levodopa Insomnia, dry mouth, nausea, orthostatic hypotension; amphetamine metabolites may cause agitation Give morning + midday to avoid insomnia. Zelapar ODT avoids first-pass metabolism → less amphetamine metabolites. DATATOP trial drug
Rasagiline Azilect Irreversible, selective MAO-B inhibitor (no amphetamine metabolites) Hepatic (CYP1A2); t½ 1.5–3.5h (but irreversible binding → duration of action outlasts t½) 0.5–1 mg once daily Monotherapy (early PD); adjunct to levodopa Headache, arthralgia, dyspepsia, orthostatic hypotension; less insomnia than selegiline No amphetamine metabolites → better tolerability than selegiline. CYP1A2 interaction: reduce dose with ciprofloxacin. ADAGIO trial drug
Safinamide Xadago Reversible, selective MAO-B inhibitor + voltage-dependent Na⁺ channel blocker + glutamate release modulation Hepatic (amidases, CYP3A4); t½ 20–26h 50–100 mg once daily Adjunct to levodopa only (not approved as monotherapy) Dyskinesia, falls, nausea, insomnia Dual mechanism may help both motor symptoms and fluctuations. Avoid with strong CYP3A4 inhibitors. Contraindicated with other MAO inhibitors, opioids (meperidine, tramadol)
Dopamine Agonists (Non-Ergot) Pramipexole Mirapex (IR), Mirapex ER Direct stimulation of post-synaptic dopamine receptors (D2/D3 preferring) Renal excretion (90% unchanged); t½ 8–12h (IR), ~12h (ER). Dose adjust for CrCl <50 IR: 0.125 mg TID → max 1.5 mg TID. ER: 0.375 mg/day → max 4.5 mg/day Monotherapy (early PD); adjunct to levodopa Somnolence/sleep attacks, nausea, hallucinations, peripheral edema, ICDs (15–25%), orthostatic hypotension CALM-PD trial drug. ER provides smoother plasma levels. D3 selectivity may explain ICD risk. Must titrate slowly; renal dose adjustment critical
Ropinirole Requip (IR), Requip XL Hepatic (CYP1A2); t½ 6h (IR), ~12h (XL). Interaction with ciprofloxacin, fluvoxamine IR: 0.25 mg TID → max 8 mg TID. XL: 2 mg/day → max 24 mg/day Monotherapy (early PD); adjunct to levodopa Same class effects as pramipexole; GI upset may be more prominent CYP1A2 substrate — dose adjust with smoking cessation or ciprofloxacin. Less D3-selective than pramipexole
Rotigotine Neupro (transdermal patch) Transdermal → steady-state in 1–2 days; hepatic (multiple CYPs); t½ 5–7h after patch removal Early PD: 2 mg/24h → max 6 mg/24h. Advanced PD: 4 mg/24h → max 8 mg/24h Monotherapy (early PD); adjunct to levodopa Application site reactions (up to 44%), somnolence, nausea, dizziness, ICDs SP512 trial drug. Continuous transdermal delivery → good for morning akinesia, dysphagia. Rotate patch sites. Store in refrigerator until use
COMT Inhibitors Entacapone Comtan; Stalevo (fixed combination with C/L) Peripheral COMT inhibition → extends levodopa plasma t½ and bioavailability (tolcapone also has central COMT inhibition) Hepatic glucuronidation; t½ 0.4–0.7h (short — dosed with each levodopa dose) 200 mg with each C/L dose (max 8×/day = 1,600 mg) Adjunct to levodopa for wearing off Diarrhea (up to 10%), orange discoloration of urine, dyskinesia (may need levodopa dose reduction), nausea Must be given with each levodopa dose. Stalevo (C/L/entacapone) simplifies regimen. STRIDE-PD: initial C/L-entacapone did not prevent, and may accelerate, dyskinesia
Opicapone Ongentys Hepatic (sulfation, glucuronidation); t½ 1–2h but irreversible COMT binding → 24h duration of action 50 mg once daily at bedtime Adjunct to levodopa for wearing off Dyskinesia, constipation, dry mouth; orange urine Once-daily dosing is a major advantage over entacapone. No hepatotoxicity signal. Take at bedtime, ≥1h from last levodopa dose
Tolcapone Tasmar Hepatic (glucuronidation, CYP3A4, 2A6); t½ 2–3h 100–200 mg TID Adjunct to levodopa (second-line due to hepatotoxicity) Hepatotoxicity (3 fatal cases reported), diarrhea (severe in ~5%), dyskinesia, orange urine Most potent COMT inhibitor; crosses BBB (central + peripheral inhibition). Requires ALT/AST monitoring q2–4 weeks × 6 months. Reserved for failure of entacapone/opicapone
A2A Antagonist Istradefylline Nourianz Selective adenosine A2A receptor antagonist → reduces indirect pathway over-activity Hepatic (CYP3A4 and CYP1A1/2); t½ ~83h (long) 20 mg once daily; may increase to 40 mg/day Adjunct to levodopa for OFF episodes Dyskinesia, dizziness, constipation, nausea, hallucinations, insomnia Non-dopaminergic mechanism → useful when further dopaminergic augmentation limited by side effects. Reduces OFF time ~0.5–0.7 h/day. Avoid with strong CYP3A4 inducers. FDA-approved 2019
NMDA Antagonist Amantadine (IR) Symmetrel, generics Weak NMDA receptor antagonist; enhances dopamine release; anticholinergic effects Renal excretion (largely unchanged); t½ 10–31h (longer with renal impairment). Dose adjust for CrCl <50 100 mg BID–TID Early PD (mild benefit); levodopa-induced dyskinesia Livedo reticularis, ankle edema, hallucinations, confusion, insomnia, anticholinergic effects; do not abruptly discontinue (risk of neuroleptic malignant-like syndrome) Modest motor benefit; primarily used for dyskinesia management. Avoid in advanced renal failure. Accumulates with impaired renal function
Amantadine (ER) Gocovri (ADS-5102), Osmolex ER Gocovri: 137 mg → 274 mg at bedtime. Osmolex: 129–322 mg each morning Gocovri: levodopa-induced dyskinesia + OFF time. Osmolex: PD motor symptoms Gocovri specifically FDA-approved for dyskinesia (EASE LID trials). Gocovri dosed at bedtime for peak levels in morning
Anticholinergics Trihexyphenidyl Artane, generics Central muscarinic (M1) receptor blockade → restores dopaminergic-cholinergic balance in striatum Hepatic; t½ 6–10h (trihexyphenidyl), ~24h (benztropine) 1 mg/day → max 6–10 mg/day in divided doses Tremor (especially in young patients); limited role overall Cognitive impairment, confusion, hallucinations, dry mouth, constipation, urinary retention, blurred vision, tachycardia Avoid in age >65 and any cognitive impairment. Most useful for tremor-predominant PD in younger patients only. Taper gradually — do not abruptly discontinue (risk of rebound)
Benztropine Cogentin, generics 0.5 mg/day → max 6 mg/day

References

  1. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord. 2018;33(8):1248–1266.
  2. Fahn S, Oakes D, Shoulson I, et al. Levodopa and the progression of Parkinson’s disease (ELLDOPA). N Engl J Med. 2004;351(24):2498–2508.
  3. Verschuur CVM, Suwijn SR, Boel JA, et al. Randomized delayed-start trial of levodopa in Parkinson’s disease (LEAP). N Engl J Med. 2019;380(4):315–324.
  4. PD MED Collaborative Group. Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson’s disease (PD MED). Lancet. 2014;384(9949):1196–1205; Gray R, et al. Long-term effectiveness of adjuvant treatment with catechol-O-methyltransferase or monoamine oxidase B inhibitors compared with dopamine agonists among patients with Parkinson disease uncontrolled by levodopa therapy (PD MED adjunct). JAMA Neurol. 2022;79(2):131–140.
  5. Parkinson Study Group. Effect of deprenyl on the progression of disability in early Parkinson’s disease (DATATOP). N Engl J Med. 1989;321(20):1364–1371.
  6. Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (ADAGIO). N Engl J Med. 2009;361(13):1268–1278.
  7. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial (CALM-PD). JAMA. 2000;284(15):1931–1938.
  8. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease (CALM-PD Long-term). Arch Neurol. 2009;66(5):563–570.
  9. Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease (SP512). Neurology. 2007;68(4):272–276.